

ACL Laboratories Implements a Race-Free Equation for Estimated Glomerular Filtration Rate (eGFR) effective April 20, 2022

The National Kidney Foundation and the American Society of Nephrology’s Task Force (NKF-ASN Task Force) have recommended that race modifiers should not be included in equations used to estimate kidney function. They recommend that current race-based equations should be replaced by a substitute that is accurate, representative, unbiased, and provides a standardized approach to diagnosing kidney diseases.

Based on these recommendations, **effective Wednesday, April 20, 2022**, ACL Laboratories will switch to the new CKD-EPI-R (2021) equation that does not include race for calculation of eGFR. The new equation has similar overall performance characteristics to old CKD-EPI 2009 and should not disproportionately affect any one group of individuals. New eGFR values will be slightly lower in individuals who identify as Black and/or African American, and slightly higher in other individuals.

ACL Laboratories reports an estimated GFR (eGFR) on all serum creatinine measurements based on recommendations by the National Kidney Foundation.

eGFR reference range remains unchanged (eGFR > 60 ml/min) and there will be no modification to the comments appended to abnormal results. These are based on the KDIGO Guidelines for the diagnosis of kidney disease:

Stage	Terms	GFR mL/min
G3a	Mildly to moderately decreased	45 to 59
G3b	Moderately to severely decreased	30-44
G4	Severely decreased	15-29
G5	Kidney failure	<15

For additional information regarding this test, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at acllaboratories.com/test-catalog/.

References:

<https://www.kidney.org/news/nkf-and-asn-release-new-way-to-diagnose-kidney-diseases>

<https://www.ajkd.org/article/S0272-63862100828-3/fulltext>

<https://jasn.asnjournals.org/content/32/12/2994>

Fentanyl and Oxycodone Drug Screens Now Performed In-House

Effective Wednesday, April 20, 2022, ACL Laboratories will offer urine Fentanyl and Oxycodone screens. Currently, these drug screens are sent to a reference laboratory for testing. Testing will be performed daily, and final laboratory results provided within 24 hours. See charts below for additional information.

Requirements	Stability	Not Acceptable
Transport Temperature: Refrigerated	Ambient: Not Acceptable Refrigerated: 7 days Frozen: 14 days	Specimens sent in preservative tubes.

Test Name	ACL Test Order Code	Cutoff	Spot Code	Notes
Fentanyl, Urine Screen	LAB11102	1.0 ng/mL	UCS	
Fentanyl, Urine Screen with Confirmation	LAB11117	1.0 ng/mL	UCS	Automatically reflexes to ARUP test Fentanyl and Metabolite, Urine, Quantitative LAB11009
Oxycodone Screen, Urine	LAB11103	100 ng/mL	UCS	

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at acllaboratories.com/test-catalog/.

Streptolysin O Antibody New Test Method

Effective Wednesday, April 20, 2022, ACL Laboratories will test Streptolysin O Antibody (ASO) on an automated platform. Currently, ASOs are performed using a manual serology method. **Reference ranges will not change; however, results will be reported as a number, not a titer.** Testing will be performed daily, and final laboratory results provided within 24 hours. See charts below for additional information.

Requirements	Stability	Not Acceptable
Transport Temperature: Refrigerated	Ambient: Not Acceptable Refrigerated: 7 days Frozen: 14 days	Grossly Lipemic or Hemolyzed specimens.

Test Name	ACL Test Order Code	Reference Ranges	Spot Code
Streptolysin O Antibody	LAB11101	0 up to 5 Years 5 Years up to 19 Years 19 Years and up	<100 IUnits/mL <250 IUnits/mL <200 IUnits/mL

For additional information regarding this test, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at acllaboratories.com/test-catalog/.